Literature DB >> 6672112

Comparison of the effects of alpha and beta interferons on the proliferation and volume of human tumor cells (HeLa-S3, Daudi, P3HR-1).

L M Pfeffer, I Tamm.   

Abstract

Treatment of three lines of tumor cells (epidermoid carcinoma: HeLa-S3, and Burkitt's lymphoma: Daudi and P3HR-1) with human alpha or beta interferon (HuIFN-alpha or HuIFN-beta) results in inhibition of cell proliferation as well as in increased modal cell volume and heterogeneity of the populations with respect to cell volume. In all three cell lines the IFN-alpha- or IFN-beta-induced changes in cell proliferation and in cell volume are inversely related to each other. However, these lines differ significantly in their sensitivity to the effects of IFN-alpha and IFN-beta.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6672112     DOI: 10.1089/jir.1983.3.395

Source DB:  PubMed          Journal:  J Interferon Res        ISSN: 0197-8357


  5 in total

1.  Interferon-alpha selectively activates the beta isoform of protein kinase C through phosphatidylcholine hydrolysis.

Authors:  L M Pfeffer; B Strulovici; A R Saltiel
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

Review 2.  Regulation of cell proliferation and differentiation by interferons.

Authors:  M J Clemens; M A McNurlan
Journal:  Biochem J       Date:  1985-03-01       Impact factor: 3.857

Review 3.  Regulation of cell growth by interferon.

Authors:  M Shearer; J Taylor-Papadimitriou
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

4.  The induction of type I interferon production in hepatitis C-infected patients.

Authors:  Lawrence M Pfeffer; Margaret A Madey; Caroline A Riely; Jaquelyn F Fleckenstein
Journal:  J Interferon Cytokine Res       Date:  2009-05       Impact factor: 2.607

5.  Interferon stimulates cholesterol and phosphatidylcholine synthesis but inhibits cholesterol ester synthesis in HeLa-S3 cells.

Authors:  L M Pfeffer; B C Kwok; F R Landsberger; I Tamm
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.